Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
atorvastatin + candesartan
- Development stage
- Phase 1
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Atorvastatin + candesartan is a fixed-dose combination of two small molecule drugs used for dual cardiovascular risk prevention. Atorvastatin is a statin that inhibits 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR), the rate-limiting enzyme in cholesterol biosynthesis, leading to reduced plasma cholesterol and LDL levels. Candesartan is an angiotensin II receptor blocker (ARB) that selectively blocks the binding of angiotensin II to the Type-1 angiotensin II receptor (AT1R) in vascular smooth muscle and adrenal glands, resulting in vasodilation and decreased blood pressure[6]. The combination targets both dyslipidemia and hypertension, providing additive benefits for patients at risk of cardiovascular events[1][4]. Clinical studies indicate that this combination can inhibit progression of atherosclerosis more effectively than statin monotherapy in patients with coronary artery disease[4], and pharmacokinetic data support its safety when coadministered[1][5].
- Brand names
- Canvastin
- Other names
- atorvastatin + candesartan
02
Targets
HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)AGTR1 (Angiotensin II Type-1 receptor)
Beyond the preview
Go deeper on atorvastatin + candesartan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on atorvastatin + candesartan.